Dublin, June 28, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Molecular Diagnostics: Infectious Disease, Genetic and Oncology Testing, Market Size, Strategies and Forecasts 2016-2019 - North America Version" report to their offering.
"Molecular Diagnostics: Infectious Disease, Genetic and Oncology Testing Market Size, Strategies and Forecasts 2016 to 2019 North America Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help understand test pricing in detail.
A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations.
Trends like:
- personalized medicine
- pharmacogenomics
- pathogen evolution
- next generation sequencing
- emergence of new economies with large markets
- greater understanding of the role of genetic material in Disease and Health
Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing.
Key Topics Covered:
1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
2. Market Overview
2.1 Market Participants
2.2 Market Segments
2.3 Industry Structure
2.4 Profiles of Key MDx Companies
2.5 Market Shares of Key MDx Players - Analysis
3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostic Definitions Create New Markets
3.1.2 Aging Population a Boon for Diagnostics.
3.1.3 Pharmacogenomics Drives Further Growth.
3.1.4 Point of Care Testing can increase demand
3.1.5 Liquid Biopsy
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs.
3.2.3 Testing usage analysis curtailing growth.
3.2.4 Wellness has a downside
3.2.5 Point of Care Testing
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 POCT/Self Testing Disruptive Force
3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.5 CGES Testing, A Brave New World
3.4.6 Biochips/Giant magneto resistance based assay
4. Molecular Diagnostics Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
5. Country Market Sizes - North America
Companies Mentioned
- 14M Genomics
- 23andMe
- Abbott Laboratories
- Abcam
- Accelerate Diagnostics'
- ACT Genomics
- Adaptive
- Aegis Sciences
- Agena Bioscience
- Agendia
- Agilent/Dako
- All About Truth DNA Services
- Allenex
- AltheaDx
- Amarantus
- Ariosa Diagnostics
- Atossa Genetics
- Avant Completes
- Baylor College of Medicin
- Becton, Dickinson & Co.
- Biofortuna
- Biological Dynamics
- BioMerieux
- BioReference Laboratories, Inc.
- Bloom Burton
- Canon US Life Sciences
- Caprion
- CardioDx
- CareDx
- Cepheid
- Claritas Genomics
- Cypher Genomics
- Cytogenetics
- DiaCarta
- Diagnovus
For more information visit http://www.researchandmarkets.com/research/psrmff/molecular